Meyka Pro banner
CONMED Corporation

CONMED Corporation (NYSE: CNMD) Stock Competitors & Peer Comparison

See CNMD's competitors and their performance on the NYSE and across the wider stock market.

CNMD●NYSE
HealthcareMedical - Devices
$46.69
$0.21(0.45%)
U.S. Market opens in 15h 26m

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for CNMD and its NYSE peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CNMD$46.69+0.45%1.4B10.26$4.55+0.43%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
ABT$100.95-0.03%174.7B19.37$5.21+2.46%
MDT$87.09-2.69%111.5B15.75$5.53+3.28%
SYK$278.77+1.26%106.9B20.83$13.39+1.25%
BSX$43.88-0.52%65.2B14.15$3.10N/A
EW$88.08+1.44%50.7B32.63$2.70N/A
DXCM$86.64-0.05%32.7B33.98$2.55N/A
GEHC$66.46-0.48%30B14.57$4.56+0.21%
PHG$24.77-1.35%24.2B14.15$1.75+4.02%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Boston Scientific Corporation (NYSE: BSX-PA)

CNMD vs BSX-PA Comparison September 2026

CONMED Corporation (NYSE: CNMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CNMD is priced at $46.69 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 10.26, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CNMD's ROE is +0.06%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CNMD is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for CNMD.Check BSX-PA's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions